ACUTE MYELOID LEUKEMIA, IN RELAPSE
Clinical trials for ACUTE MYELOID LEUKEMIA, IN RELAPSE explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA, IN RELAPSE trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough leukemias: experimental drug APL-4098 enters human testing
Disease control Recruiting nowThis early-stage study tests an experimental drug called APL-4098, alone or with standard chemotherapy drugs, in about 100 adults with acute myeloid leukemia (AML) or related blood cancers that have come back or not responded to treatment. The main goals are to check safety, find…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated May 17, 2026 00:47 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called CD371-YSNVZ-IL18 CAR T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find the safest dose and see what side effects occur. About 15 participants w…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 00:47 UTC
-
New immune therapy combo shows promise in early AML trial
Disease control Recruiting nowThis study tests a new treatment for acute myeloid leukemia (AML) that uses a patient's own immune cells, trained to attack the cancer, combined with standard chemotherapy drugs. About 30 adults with AML will receive this therapy to see if it is safe and works. The goal is to imp…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: David Avigan • Aim: Disease control
Last updated May 17, 2026 00:43 UTC
-
New immune cell therapy takes on tough childhood leukemia
Disease control Recruiting nowThis early-stage study tests a new treatment called SC-DARIC33 for children and young adults up to age 30 whose acute myeloid leukemia (AML) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are genetically modified to be…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated May 17, 2026 00:29 UTC
-
New combo therapy offers hope for young leukemia patients who've relapsed
Disease control Recruiting nowThis early-stage study tests whether adding the drug venetoclax to two other medications (5-azacitidine and vorinostat) followed by standard chemotherapy can improve treatment response in children and young adults with acute myeloid leukemia that has come back or not responded to…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug combo shows promise for Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage study tests whether adding the experimental drug ziftomenib to standard AML treatments is safe and effective. About 420 adults with specific genetic mutations (NPM1 or KMT2A) will receive one of three drug combinations. The goal is to find the best dose and see i…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New immune cell therapy targets relapsed leukemia and MDS
Disease control Recruiting nowThis early-stage study tests a pre-made immune cell therapy (MT-401-OTS) for people aged 65+ with relapsed acute myeloid leukemia or high-risk myelodysplastic syndromes. The therapy uses donor T-cells designed to attack multiple cancer-related targets. The main goals are to check…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Marker Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for tough leukemia: daily drug trial opens
Disease control Recruiting nowThis study tests a daily intravenous drug called AB8939 in adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatments. The main goal is to find a safe dose and see if the drug can shrink or control the cancer. About 78 participants will take p…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: AB Science • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for tough blood cancers: ARD103 trial opens
Disease control Recruiting nowThis study tests a new drug called ARD103 in about 49 adults whose acute myeloid leukemia or myelodysplastic syndrome has returned or not improved with standard treatments. The goal is to find a safe dose and see if the drug can shrink or control the cancer. Participants will rec…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: ARCE Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Immune cell booster shot targets tough leukemia
Disease control Recruiting nowThis early-phase study tests a new treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment combines specially trained natural killer (NK) cells with a drug called atezolizumab, which may help the immune system …
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for tough leukemia: tiny fat bubbles deliver targeted therapy
Disease control Recruiting nowThis early-phase study tests a new drug called C6 ceramide NanoLiposome (CNL) in 15 adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also watch…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Keystone Nano, Inc • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
New hope for hard-to-treat leukemia: experimental combo enters human testing
Disease control Recruiting nowThis early-phase study tests a new two-drug combination (bomedemstat plus venetoclax) in 18 adults whose acute myeloid leukemia (AML) has returned or not responded to standard therapy. The main goal is to find a safe dose and understand side effects. Researchers will also check i…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Terrence J Bradley, MD • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
4,000 leukemia patients tracked to see what treatments work best in real life
Knowledge-focused Recruiting nowThis study will follow 4,000 adults whose acute myeloid leukemia has come back or not responded to treatment. Researchers will collect information on which treatments patients receive and how long they live, without giving any new medicine themselves. The goal is to learn what re…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated May 15, 2026 11:58 UTC